Nanotechnology: A reality for diagnosis of HCV infectious disease

Arca-Lafuente, Sonia; Martínez-Román, Paula; Maté-Cano, Irene; Madrid, Rodolfo; Briz, Verónica

doi:10.1016/j.jinf.2019.09.010

Cited by 24 publications

(22 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several examples are presented in Table 2 and described in Section 5. Recently, Arca-Lafuente et al [163] overviewed nanotechnology-based systems as reliable alternative diagnostic tools for HCV infectious disease. Even if our review does not cover screening, it is important to mention that new diagnostic methods are required in order to overcome current drawbacks of HCV under-diagnosed infection as highlighted in the above-mentioned review.…”

Section: Nanotechnology: How Does It Face the Antiviral Therapy?mentioning

confidence: 99%

Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers

et al. 2020

View full text Add to dashboard Cite

Viral infections are a major global health problem, representing a significant cause of mortality with an unfavorable continuously amplified socio-economic impact. The increased drug resistance and constant viral replication have been the trigger for important studies regarding the use of nanotechnology in antiviral therapies. Nanomaterials offer unique physico-chemical properties that have linked benefits for drug delivery as ideal tools for viral treatment. Currently, different types of nanomaterials namely nanoparticles, liposomes, nanospheres, nanogels, nanosuspensions and nanoemulsions were studied either in vitro or in vivo for drug delivery of antiviral agents with prospects to be translated in clinical practice. This review highlights the drug delivery nanosystems incorporating the major antiviral classes and their transport across specific barriers at cellular and intracellular level. Important reflections on nanomedicines currently approved or undergoing investigations for the treatment of viral infections are also discussed. Finally, the authors present an overview on the requirements for the design of antiviral nanotherapeutics.

show abstract

Section: Nanotechnology: How Does It Face the Antiviral Therapy?mentioning

confidence: 99%

Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To overcome the problems caused by traditional diagnosis approaches, nanomedicine can be combined with these methods for better management of UTIs. Nanostructures are more effective in preventing toxicity and resistance and reducing the costs of more traditional methods [91][92][93][94]. The current UTI diagnosis methods and nanotechnological approaches are presented in Figure 1.…”

Section: Diagnosis Of Utis By Nanotechnologymentioning

confidence: 99%

Nanomaterials for the Diagnosis and Treatment of Urinary Tract Infections

et al. 2021

View full text Add to dashboard Cite

The diagnosis and treatment of urinary tract infections (UTIs) remain challenging due to the lack of convenient assessment techniques and to the resistance to conventional antimicrobial therapy, showing the need for novel approaches to address such problems. In this regard, nanotechnology has a strong potential for both the diagnosis and therapy of UTIs via controlled delivery of antimicrobials upon stable, effective and sustained drug release. On one side, nanoscience allowed the production of various nanomaterial-based evaluation tools as precise, effective, and rapid procedures for the identification of UTIs. On the other side, nanotechnology brought tremendous breakthroughs for the treatment of UTIs based on the use of metallic nanoparticles (NPs) for instance, owing to the antimicrobial properties of metals, or of surface-tailored nanocarriers, allowing to overcome multidrug-resistance and prevent biofilm formation via targeted drug delivery to desired sites of action and preventing the development of cytotoxic processes in healthy cells. The goal of the current study is therefore to present the newest developments for the diagnosis and treatment of UTIs based on nanotechnology procedures in relation to the currently available techniques.

show abstract

“…Scientific interest in nanoparticles is on the rise, due to their versatility and especially their wide applicability. Owing to the conversion of pure metals into nanoparticles, nanotechnology has become a powerful research technique in medical sciences and is used in the diagnosis of diseases, for carrying drugs, and even for their antimicrobial and anticancer activities [42,50,51]. These infinitesimal particles, produced using varying methods and used in different formats and compositions, are capable of transporting substances into the body, improving therapeutic efficacy and decreasing toxicity of the substance carried [43,44,52].…”

Section: New Perspectives For the Treatment Of Viral Diseasesmentioning

confidence: 99%

Antiviral therapies: advances and perspectives

Gonçalves

Barbosa

Olak

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Viral infections cause high morbidity and mortality, threaten public health, and impose a socioeconomic burden. We have seen the recent emergence of SARS‐CoV‐2 (Severe Acute Respiratory Syndrome Coronavirus 2), the causative agent of COVID‐19 that has already infected more than 29 million people, with more than 900 000 deaths since its identification in December 2019. Considering the significant impact of viral infections, research and development of new antivirals and control strategies are essential. In this paper, we summarize 96 antivirals approved by the Food and Drug Administration between 1987 and 2019. Of these, 49 (51%) are used in treatments against human immunodeficiency virus (HIV), four against human papillomavirus, six against cytomegalovirus, eight against hepatitis B virus, five against influenza, six against herpes simplex virus, 17 against hepatitis C virus and one against respiratory syncytial virus. This review also describes future perspectives for new antiviral therapies such as nanotechnologies, monoclonal antibodies and the CRISPR‐Cas system. These strategies are suggested as inhibitors of viral replication by various means, such as direct binding to the viral particle, blocking the infection, changes in intracellular mechanisms or viral genes, preventing replication and virion formation. We also observed that a large number of viral agents have no therapy available and the majority of those approved in the last 32 years are restricted to some groups, especially anti‐HIV. Additionally, the emergence of new viruses and strains resistant to available antivirals has necessitated the formulation of new antivirals.

show abstract

Nanotechnology: A reality for diagnosis of HCV infectious disease

Cited by 24 publications

References 68 publications

Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers

Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers

Nanomaterials for the Diagnosis and Treatment of Urinary Tract Infections

Antiviral therapies: advances and perspectives

Contact Info

Product

Resources

About